RESTART C0168Z05 Rheumatoid Arthritis Study
A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Hamilton Ontario, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Newfoundland and Labrador
-
St. John'S, Newfoundland and Labrador, Canada
-
-
Ontario
-
Toronto, Ontario, Canada
-
-
-
-
-
Leeds, Det Forenede Kongerige
-
London, Det Forenede Kongerige
-
Wigan, Det Forenede Kongerige
-
-
-
-
-
Helsinki, Finland
-
-
-
-
Alabama
-
Huntsville, Alabama, Forenede Stater
-
-
Arizona
-
Paradise Valley, Arizona, Forenede Stater
-
Tucson, Arizona, Forenede Stater
-
-
California
-
Santa Monica, California, Forenede Stater
-
-
Connecticut
-
Bridgeport, Connecticut, Forenede Stater
-
-
Delaware
-
Lewes, Delaware, Forenede Stater
-
-
Florida
-
Boca Raton, Florida, Forenede Stater
-
Palm Harbor, Florida, Forenede Stater
-
Tamarac, Florida, Forenede Stater
-
Vero Beach, Florida, Forenede Stater
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater
-
-
Illinois
-
Moline, Illinois, Forenede Stater
-
Springfield, Illinois, Forenede Stater
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater
-
-
Maryland
-
Wheaton, Maryland, Forenede Stater
-
-
Michigan
-
Saint Clair Shores, Michigan, Forenede Stater
-
-
Minnesota
-
Eagan, Minnesota, Forenede Stater
-
-
Missouri
-
Saint Louis, Missouri, Forenede Stater
-
Springfield, Missouri, Forenede Stater
-
-
New Jersey
-
Berkeley Heights, New Jersey, Forenede Stater
-
Freehold, New Jersey, Forenede Stater
-
-
New York
-
Albany, New York, Forenede Stater
-
Syracuse, New York, Forenede Stater
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater
-
-
Ohio
-
Columbus, Ohio, Forenede Stater
-
Mayfield, Ohio, Forenede Stater
-
Middleburg Heights, Ohio, Forenede Stater
-
-
Oklahoma
-
Tulsa, Oklahoma, Forenede Stater
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater
-
Duncansville, Pennsylvania, Forenede Stater
-
Wexford, Pennsylvania, Forenede Stater
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater
-
Greenville, South Carolina, Forenede Stater
-
-
Tennessee
-
Jackson, Tennessee, Forenede Stater
-
Nashville, Tennessee, Forenede Stater
-
-
Texas
-
Amarillo, Texas, Forenede Stater
-
Dallas, Texas, Forenede Stater
-
Fort Worth, Texas, Forenede Stater
-
Houston, Texas, Forenede Stater
-
Mesquite, Texas, Forenede Stater
-
Temple, Texas, Forenede Stater
-
Tyler, Texas, Forenede Stater
-
-
Virginia
-
Burke, Virginia, Forenede Stater
-
Reston, Virginia, Forenede Stater
-
-
Washington
-
Seattle, Washington, Forenede Stater
-
-
-
-
-
Bordeaux Cedex, Frankrig
-
Limoges, Frankrig
-
Montivilliers, Frankrig
-
Orleans, Frankrig
-
-
-
-
-
Alkmaar, Holland
-
-
-
-
-
Ashkelon, Israel
-
Beer Yaakov, Israel
-
Haifa, Israel
-
Kfar Saba, Israel
-
Ramat Gan, Israel
-
Rehovot, Israel
-
Tel-Aviv, Israel
-
-
-
-
-
Madrid, Spanien
-
Oviedo, Spanien
-
Santiago De Compostela, Spanien
-
-
-
-
-
Frankfurt, Tyskland
-
Holdenfelde, Tyskland
-
Leipzig, Tyskland
-
Muenchen, Tyskland
-
München, Tyskland
-
Ratingen, Tyskland
-
-
-
-
-
Graz-Eggenberg, Østrig
-
Wien, Østrig
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients must have rheumatoid arthritis
- Patients must have greater than or equal to 6 tender joints and greater than or equal to 6 swollen joints
- Patients must have inadequate disease response to etanercept or adalimumab
- Patients must have received etanercept or adalimumab in combination with methotrexate for a minimum of at least 3 months prior to the screening visit. The last dose of etanercept must have been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion.
Exclusion Criteria:
- Patients who have a history of latent or active TB
- Have inflammatory disease other than rheumatoid arthritis
- Have had a chronic or recurrent infectious disease.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Andet: 001
Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
|
3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10
Tidsramme: Week 10
|
Percent of patients who achieved EULAR response at Week 10.
EULAR response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999).
At a given visit, patients with a DAS28 score of ≤ 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is greater than 0.6; Or patients with a DAS28 score > 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is > 1.2.
|
Week 10
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent of Patients Who Acheived EULAR Response at Week 10 and Maintained Through Week 26 Without Infliximab Dose Increase
Tidsramme: Week 26
|
Percent of patients who achieved EULAR response at Week 10 and maintained through Week 26 without infliximab dose increase
|
Week 26
|
|
Percent of Patients Who Achieved EULAR Response at Week 26, Regardless of EULAR Response Status at Weeks 10, 14, and 22, With or Without Dose Increase Prior to Week 26
Tidsramme: Week 26
|
Percent of patients who achieved EULAR response at Week 26, regardless of EULAR response status at Weeks 10, 14, and 22, with or without dose increase prior to Week 26
|
Week 26
|
|
Change From Baseline in Physical Function (HAQ)
Tidsramme: Week 10
|
Change from baseline in physical function (HAQ) at Week 10.
HAQ assesses the degree of difficulty a person has in accomplishing tasks.
A lower HAQ score indicates less difficulty.
Change from baseline is computed as Week 10 value minus baseline value.
A negative value in change from baseline indicates an improvement.
|
Week 10
|
|
Change From Baseline in Physical Function (HAQ)
Tidsramme: Week 26
|
Change from baseline in physical function (HAQ) at Week 26.
HAQ assesses the degree of difficulty a person has in accomplishing tasks.
A lower HAQ score indicates less difficulty.
Change from baseline is computed as Week 26 value minus baseline value.
A negative value in change from baseline indicates an improvement.
|
Week 26
|
|
Percent of Patients Who Achieved ACR20 at Week 10
Tidsramme: Week 10
|
Percent of patients who achieved ACR20 at Week 10.
A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.
|
Week 10
|
|
Percent of Patients Who Achieved ACR20 at Weeks 26.
Tidsramme: Week 26
|
Percent of patients who achieved ACR20 at Weeks 26.
A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.
|
Week 26
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CR013879
- C0168Z05 (Anden identifikator: Centocor Ortho Biotech Services, L.L.C.)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .